Skip to main content

Table 1 Blood pressure and basic biochemistry at baseline and after the 28-day treatment with fenofibrate or placebo

From: Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status

Parameter

Baseline

After Placebo

After Fenofibrate

Systolic blood pressure [mmHg]

138 ± 17

137 ± 12

134 ± 11

Diastolic blood pressure [mmHg]

91 ± 22

92 ± 18

93 ± 23

S-sodium [mmol/L]

139 ± 3

137 ± 3*

138 ± 3

S-potassium [mmol/L]

5.1 ± 0.9

5.1 ± 0.8

5.2 ± 0.8

S-albumin [g/L]

37.9 ± 3.4

38.4 ± 2.8

38.3 ± 3.3

S-urea [mg/dL]

128.2 ± 36.0

134.0 ± 28.1

139.1 ± 28.9

S-creatinine [mg/dl]

8.7 ± 2.4

8.8 ± 2.3

8.8 ± 2.3

S-GOT [IU/L]

21.1 ± 12.8

22.6 ± 9.1

23.3 ± 22.6

S-Creatine kinase [IU]

78.9 ± 48.8

72.9 ± 49.7

95.3 ± 63.9#

S-CRP [mg/L]

6.4 ± 5.2

7.2 ± 7.6

7.9 ± 9.1

  1. # p = 0.01 vs baseline; * p < 0.05 vs baseline